We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Reunion Neuroscience Inc | TSX:REUN | Toronto | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.42 | 1.02 | 1.49 | 0 | 00:00:00 |
TORONTO, Oct. 25, 2022 /CNW/ - Greg Mayes, President & Chief Executive Officer; Nathan Bryson, Chief Science Officer, and other members of the Reunion Neuroscience Inc. (TSX: REUN) management team joined Karoline Hunter, Head, Company Services, Toronto Stock Exchange (TSX), to celebrate the Company's new listing on Toronto Stock Exchange and open the market.
Previously the drug development division of Field Trip Health Ltd. under the name Field Trip Discovery, Reunion Neuroscience Inc. is now an independent public company focused on novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The Company's lead asset, RE-104, is a proprietary, novel psychedelic drug being developed for postpartum depression and treatment-resistant depression as a potential fast-acting antidepressant with durable efficacy.
SOURCE Toronto Stock Exchange
Copyright 2022 Canada NewsWire
1 Year Reunion Neuroscience Chart |
1 Month Reunion Neuroscience Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions